SEC Secures Final Judgment Against Gerard Ryan in Kadmon Insider Trading Case
SEC finalizes Gerard Ryan’s insider trading case over 16,480 Kadmon shares, imposing $9,258 disgorgement, probation and a $25,000 criminal fine in New York.
Summary
In Litigation Release No. 26691 dated November 20, 2026, the SEC said the Southern District of New York entered a final consent judgment against Gerard Ryan on November 18. The SEC’s June 4, 2026 complaint, Securities and Exchange Commission v. Gerard Ryan, No. 26-civ-4724, alleged Ryan learned from a family member in Kadmon Holdings, Inc.’s Commercial Sales Department that the FDA confidentially told Kadmon on July 14, 2021 it planned to approve Rezurock. Ryan allegedly bought approximately 16,480 Kadmon shares before the July 16 public approval announcement, tipped a friend who also traded, and generated $9,258 in profits based on that day’s closing price.
A June 12, 2026 partial judgment permanently enjoined Ryan from violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The final judgment reimposed that relief and ordered $9,258 of disgorgement, satisfied by forfeiture in United States v. Ryan, 26 cr. 00117. Ryan pleaded guilty to one securities fraud count and received two years of probation, $9,258 in forfeiture and a $25,000 criminal fine. Cynthia A. Matthews, Neil Hendelman, Frank Milewski, John Rymas and Lindsay S. Moilanen conducted the SEC investigation, supervised by Market Abuse Unit Chief Joseph Sansone. Elisa S. Solomon, Matthews and Moilanen led the litigation under Jack Kaufman.
Positives
- The November 18 final consent judgment resolves the SEC case and reimposes permanent antifraud injunctive relief against Ryan.
- The $9,258 disgorgement obligation is satisfied through forfeiture ordered in the parallel federal criminal case.
- Ryan’s guilty plea produced two years of probation, $9,258 in forfeiture and a $25,000 criminal fine.
Risks & concerns
- The SEC alleged confidential FDA approval information passed from a Kadmon employee to family member Gerard Ryan.
- Ryan allegedly bought approximately 16,480 Kadmon shares before the July 16, 2021 public Rezurock approval announcement.
- Ryan allegedly tipped a friend who also traded before Kadmon disclosed the FDA approval.
- The alleged trading generated $9,258 in profits based on Kadmon’s July 16 closing share price.